Skip to main content
Donate
Login
IASLC's 50th Anniversary
IASLC's 50th Anniversary
History
Support The Mission
Support The Mission
Partners for Thoracic Cancer Care
Legacy Society
IASLC Global Member Survey on Inclusivity
About Us
About Us
Strategic Plan
Board of Directors
Committees
Awards
Staff
Careers
Contact
Search
Donate
Login
Conferences & Webinars
Conferences & Webinars
Upcoming Conferences & Webinars
Past Conferences & Webinars
WCLC 2023 Highlights
Research & Education
Research & Education
Publications, Resources & Guidelines
Journals
Journals
Journal of Thoracic Oncology
JTO Clinical and Research Reports (JTO CRR)
IASLC Reviewer Workshop
Lung Cancer 360
Research Projects
Research Projects
Staging Project
IASLC Global Survey on Biomarker Testing in Lung Cancer 2024 Update
IASLC Neoadjuvant Therapy in Lung Cancers Initiatives
IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer
ELIC
Early-Career Opportunities
News
News
ILCN
Press Releases
Lung Cancer Considered Podcast
Membership
Membership
Become a Member
Renew Your Membership
Partner Society Membership Offers
Patient Advocacy
Patient Advocacy
STARS
Advocacy Partner Spotlight
Lung Cancer Awareness Month 2023 Highlights
Foundation
Foundation
Donor Recognition
Research Grant Program
Grant Recipient Spotlights
Research Grant Recipients
Search
Fulltext search
Fulltext search
Search
Displaying 1 - 9 items out of 9 results
ILCN article
More Options Needed After First-Line Chemoimmunotherapy in Lung Cancer
ILCN article
Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC
ILCN article
IASLC Studying Impact of COVID-19 on International Lung Cancer Clinical Trial Enrollment, Mitigation Strategies
ILCN article
Cancer Clinical Trial Compensation: Undue or Long Overdue?
ILCN article
Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials
ILCN article
Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials
ILCN article
Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma
ILCN article
The New WHO Classification of Lung Tumors
ILCN article
Lung Cancer Biomarker Testing Patterns Varied Widely in Japan